A Phase 1 interventional study of MEDI2338 and MEDI2338 in Chronic Obstructive Pulmonary Disease, sponsored by MedImmune LLC. Completed at 4 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-10-23.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 160th largest by enrollment of the 194 interventional ones that give a count, is one of 28 that started in 2011, is one of 42 in phase 1, and was the 92nd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 28 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump
Biological: MEDI2338
MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
Biological: MEDI2338
MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
Biological: MEDI2338
MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
Biological: MEDI2338
MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
Biological: MEDI2338
Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
Other: Placebo
MEDI2338 single intravenous (IV) dose (lowest dose)
MEDI2338 single IV dose (next highest dose)
MEDI2338 single IV dose (next highest dose)
MEDI2338 single IV dose (next highest dose)
MEDI2338 single IV dose (highest dose)
Placebo single IV dose
Incidence of Adverse Events
Number of participants experiencing adverse events (includes both adverse events and serious adverse events)
Time frame: Days 1 - 92
Incidence of Serious Adverse Events
Number of participants experiencing serious adverse events
Time frame: Days 1 - 92
Incidence of Clinically Significant Hematology Laboratory Results
Number of participants experiencing clinically significant hematology laboratory results. A clinically significant hematology laboratory result is defined as an abnormal hematology laboratory result that results in a treatment-emergent adverse event.
Time frame: Days 1 - 92
Incidence of Clinically Significant Electrocardiogram Results
Number of participants experiencing clinically significant electrocardiogram results. A clinically significant electrocardiogram result is defined as an abnormal electrocardiogram result that results in a treatment-emergent adverse event.
Time frame: Days 1 - 92
Incidence of Clinically Significant Vital Signs Results
Number of participants experiencing clinically significant vital signs results. A clinically significant vital signs result is defined as an abnormal vital signs result that results in a treatment-emergent adverse event.
Time frame: Days 1 - 92
Incidence of Clinically Significant Serum Chemistry Laboratory Results
Number of participants experiencing clinically significant serum chemistry laboratory results. A clinically significant serum chemistry laboratory result is defined as an abnormal serum chemistry laboratory result that results in a treatment-emergent adverse event.
Time frame: Days 1 - 92
Area Under the Serum Concentration-Time Curve From Time Zero to Infinity
Area under the serum concentration-time curve from time zerio to infinity of MEDI2338
Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Area Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point
Area under the serum concentration-time profile from time zero to the last measurable time point of MEDI2338
Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Incidence of Anti-drug Antibodies (ADA) to MEDI2338
Number of participants with ADA to MEDI2338
Time frame: Days 1, 57, and 92
Observed Maximum Concentration (Cmax)
Cmax of MEDI2338
Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Apparent Terminal Elimination Phase Half-life (t1/2)
t1/2 of MEDI2338
Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Clearance (CL)
CL of MEDI2338
Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
A total of 31 participants provided written informed consent and participated in the study at 3 sites in South Africa (2 sites) and the United Kingdom (1 site) between 24Feb2011 and 25Nov2011.
| Milestone | Placebo | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG |
|---|---|---|---|---|---|---|
| Started | 6 | 3 | 3 | 6 | 7 | 6 |
| Completed | 6 | 3 | 3 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants experiencing adverse events (includes both adverse events and serious adverse events)
| Participants | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Incidence of Adverse Events | 3 | 3 | 6 | 7 | 5 | 6 |
Number of participants experiencing serious adverse events
| Participants | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Incidence of Serious Adverse Events | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants experiencing clinically significant hematology laboratory results. A clinically significant hematology laboratory result is defined as an abnormal hematology laboratory result that results in a treatment-emergent adverse event.
| Participants | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Incidence of Clinically Significant Hematology Laboratory Results | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants experiencing clinically significant electrocardiogram results. A clinically significant electrocardiogram result is defined as an abnormal electrocardiogram result that results in a treatment-emergent adverse event.
| Participants | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Incidence of Clinically Significant Electrocardiogram Results | 0 | 0 | 0 | 0 | 0 | 1 |
Number of participants experiencing clinically significant vital signs results. A clinically significant vital signs result is defined as an abnormal vital signs result that results in a treatment-emergent adverse event.
| Participants | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Incidence of Clinically Significant Vital Signs Results | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants experiencing clinically significant serum chemistry laboratory results. A clinically significant serum chemistry laboratory result is defined as an abnormal serum chemistry laboratory result that results in a treatment-emergent adverse event.
| Participants | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Incidence of Clinically Significant Serum Chemistry Laboratory Results | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the serum concentration-time curve from time zerio to infinity of MEDI2338
| ng x day/mL | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Area Under the Serum Concentration-Time Curve From Time Zero to Infinity | 27550.5 ± 8163.6 | 104751.1 ± 40826.2 | 281781.5 ± 61554.1 | 915668.6 ± 342545.7 | 3081728.5 ± 846989.4 | — |
Area under the serum concentration-time profile from time zero to the last measurable time point of MEDI2338
| ng x day/mL | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Area Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point | 24427.8 ± 8086.4 | 87549.7 ± 31391.2 | 250155.6 ± 40613.8 | 846433.3 ± 303849.8 | 2909818.8 ± 812729.7 | — |
Number of participants with ADA to MEDI2338
| Participants | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Incidence of Anti-drug Antibodies (ADA) to MEDI2338 | 0 | 0 | 0 | 0 | 0 | — |
Cmax of MEDI2338
| ng/mL | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Observed Maximum Concentration (Cmax) | 2458.0 ± 589.1 | 9722.2 ± 4376.8 | 27122.6 ± 2845.9 | 106042.5 ± 23883.9 | 337004.5 ± 51793.8 | — |
t1/2 of MEDI2338
| Days | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Apparent Terminal Elimination Phase Half-life (t1/2) | 34.85 ± 5.30 | 40.85 ± 3.51 | 28.46 ± 3.37 | 26.76 ± 5.54 | 24.87 ± 3.27 | — |
CL of MEDI2338
| L/Days | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Placebo |
|---|---|---|---|---|---|---|
| Clearance (CL) | 0.387 ± 0.125 | 0.312 ± 0.099 | 0.365 ± 0.071 | 0.360 ± 0.110 | 0.346 ± 0.097 | — |
Collected over Days 1-92. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/6 (0%) | 6/6 (100%) |
| MEDI2338 10 MG | — | 0/3 (0%) | 3/3 (100%) |
| MEDI2338 30 MG | — | 0/3 (0%) | 3/3 (100%) |
| MEDI2338 100 MG | — | 0/6 (0%) | 6/6 (100%) |
| MEDI2338 300 MG | — | 0/7 (0%) | 7/7 (100%) |
| MEDI2338 1000 MG | — | 0/6 (0%) | 5/6 (83.3%) |
| Event | Placebo | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG |
|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/6 | 0/3 | 2/3 | 1/6 | 1/7 | 1/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 2/3 | 1/3 | 0/6 | 1/7 | 0/6 |
| BradycardiaCardiac disorders | 0/6 | 0/3 | 0/3 | 2/6 | 0/7 | 1/6 |
| ToothacheGastrointestinal disorders | 0/6 | 1/3 | 0/3 | 1/6 | 0/7 | 0/6 |
| NasopharyngitisInfections and infestations | 0/6 | 0/3 | 1/3 | 0/6 | 0/7 | 1/6 |
| SinusitisInfections and infestations | 2/6 | 0/3 | 0/3 | 0/6 | 0/7 | 0/6 |
| ContusionInjury, poisoning and procedural complications | 1/6 | 0/3 | 1/3 | 0/6 | 0/7 | 0/6 |
| LacerationInjury, poisoning and procedural complications | 2/6 | 0/3 | 0/3 | 0/6 | 1/7 | 0/6 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/6 | 0/3 | 1/3 | 0/6 | 1/7 | 0/6 |
| DizzinessNervous system disorders | 0/6 | 0/3 | 1/3 | 2/6 | 1/7 | 1/6 |
| Age Continuous(Years) | Placebo | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Total |
|---|---|---|---|---|---|---|---|
| Mean | 61.3 ± 8.0 | 57.0 ± 4.0 | 59.7 ± 11.0 | 60.3 ± 7.1 | 55.1 ± 5.3 | 60.8 ± 6.0 | 59.1 ± 6.8 |
| Sex: Female, Male(Participants) | Placebo | MEDI2338 10 MG | MEDI2338 30 MG | MEDI2338 100 MG | MEDI2338 300 MG | MEDI2338 1000 MG | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 1 | 2 | 2 | 2 | 0 | 11 |
| Male | 2 | 2 | 1 | 4 | 5 | 6 | 20 |
The record gives a start of Mar 2011, a primary completion of Nov 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Camoteskimab
Pulmonary Disease, Chronic Obstructive →